Mylan Pharmaceuticals has begun marketing the first generic version of Sanofi Aventis’ BenzaClin.

The preparation, the first to be approved by the US Food and Drug Administration (FDA), consists of 1% clindamycin and 5% benzoyl peroxide gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International.

Dow received FDA approval for its for clindamycin 1% and benzoyl peroxide 5% gel, a prescription-strength topical antibiotic used to treat acne, on 11 August.

BenzaClin had total US sales of approximately $221m for the 12 months ending 30 June.